At MediMix, we are dedicated to keeping Belgian healthcare professionals at the forefront of medicine. Our team brings you high-value insights from leading congresses worldwide, across key disease areas including hematology. In collaboration with Belgian and international experts, we transform the latest data into practical knowledge.
In this video, Prof Dr Stephan Mielke presents a pooled longitudinal safety analysis of lisocabtagene maraleucel (liso-cel) in 420 patients with relapsed or refractory large B-cell lymphoma.
In this video, Dr Jan Brijs discusses a post hoc analysis of the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials presented at the 2026 European Hematology Association (EHA) Congress.
In this video, Dr Adriano Salaroli discusses two poster presentations on myelofibrosis, with a particular focus on the use of momelotinib and the management of cytopenic disease.
New data presented at the 2026 annual meeting of the European Hematology Association (EHA)by Prof Dr Elias Jabbour highlight the potential of a new subcutaneous formulation of blinatumomab in patients
In this video, Dr Marie Vercruyssen summarizes updated results from the pivotal phase III DREAMM-7 and DREAMM-8 trials presented during the 2026 annual meeting of the European Hematology Association. Both
In this video, Prof Dr Marie-Christiane Vekemans discusses an indirect comparison of two BCMA-targeted regimens in relapsed or refractory multiple myeloma.
In this video, Prof Dr Catherine Thieblemont discusses real-world data on healthcare resource utilization after CAR T-cell therapy in relapsed or refractory large B-cell lymphoma.
In this video, Dr Frida Bugge Askeland discusses primary results from the phase II portion of the REMNANT study in newly diagnosed, transplant-eligible multiple myeloma.
